Author

Sarah Ridd

Observed name: S. Ridd

Institutions: University Health Network, Princess Margaret Cancer Centre

Observed institutions: Ontario Institute for Cancer Research, University Health Network, Princess Margaret Cancer Centre, McMaster University

ORCID: 0000-0001-9444-3803

Observed ORCID: 0000-0001-9444-3803

OpenAlex ID: A5019617404

Wearable Inertial Sensors for Gait Analysis in Adults with Osteoarthritis—A Scoping Review

2020 · Dylan Kobsar, Zaryan Masood, et al. · Sensors · 97

CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase

2022 · Kilannin Krysiak, Arpad M Danos, et al. · Nucleic Acids Research · 42

Developing a disease-specific annotation protocol for VHL gene curation using Hypothes.is

2023 · Dena Salehipour, Kirsten M Farncombe, et al. · Database · 6

Wearable inertial sensors for gait analysis in adults with osteoarthritis – a scoping review

2021 · D. Kobsar, Z. Masood, et al. · Osteoarthritis and Cartilage · 4

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium

2026 · Kirsten M. Farncombe, Julia A. Sobotka, et al. · European Journal of Human Genetics · 3

Multiplatform curation in the development of ACMG/AMP specifications for Von Hippel-Lindau (VHL) disease

2026 · Deborah I. Ritter, Chansonette Badduke, et al. · Genetics in Medicine · 2

P548: Universal germline genetic testing for breast cancer at the Princess Margaret Cancer Centre

2024 · Larissa Peck, Maria Carolina Sanabria-Salas, et al. · Genetics in Medicine Open · 1

O16: The new normal: Six years of mainstreaming germline genetic testing across cancer sites

2024 · Larissa Peck, Sarah Ridd, et al. · Genetics in Medicine Open · 1

Costs and Benefits of Universal Germline Genetic Testing in Breast Cancer for Ovarian Cancer Prevention

2026 · Janice S. Kwon, Larissa Peck, et al. · International Journal of Gynecological Cancer

Abstract B053: A randomized controlled trial for hereditary cancer in the cfDNA in Hereditary And High-Risk Malignancies (CHARM) consortium: Neurofibromatosis type 1 cohort

2026 · Kirsten M. Farncombe, Sarah Ridd, et al. · Cancer Research

LLM-based data extraction for a large cancer registry, the Ontario Hereditary Cancer Research Network

2025 · Andres Felipe Melani De La Hoz, Jochen Weile, et al. · medRxiv

Myelodysplastic syndrome diagnosed by genetic testing for hereditary cancer: a case report

2025 · Sarah Ridd, Larissa Peck, et al. · npj Genomic Medicine

P103: Operationalizing structured curated scientific literature (CIViC and Hypothesis) in developing gene-specific recommendations of the ClinGen VHL Variant Curation Expert Panel

2024 · Deborah Ritter, Chansonette Badduke, et al. · Genetics in Medicine Open

P108: Myelodysplastic syndrome (MDS) detected by germline genetic testing for hereditary cancer

2024 · Larissa Peck, Sarah Ridd, et al. · Genetics in Medicine Open

Works count: 14

Citation count: 156

H-index: 4

I10-index: 2